Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 15/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 15/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 15/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 15/20 | 0.44 |
| ▸ | BACE1 | P56817 | 3/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3367313 | 0.88 | PDE4A (0.45) | PDE4APDE4BPDE4CPDE4DBACE1 | |
| SCHEMBL5532712 | 0.85 | PDE4A (0.41) | PDE4APDE4BPDE4CPDE4DBACE1 | |
| SCHEMBL5536001 | 0.84 | BACE1 (0.38) | BACE1CYP2D6BACE2 | |
| SCHEMBL3362216 | 0.77 | BACE1 (0.58) | PDE4APDE4BPDE4CPDE4DBACE1 | |
| SCHEMBL1634605 | 0.76 | BACE1 (0.39) | PDE4APDE4BPDE4CPDE4DBACE1 | |
| SCHEMBL3367165 | 0.76 | BACE1 (0.59) | PDE4APDE4BPDE4CPDE4DBACE1 | |
| SCHEMBL3367319 | 0.70 | ADORA1 (0.41) | BACE1CYP2D6BACE2 | |
| SCHEMBL10615392 | 0.68 | SIGMAR1 (0.54) | PDE4APDE4BPDE4CPDE4DBACE1 | |
| SCHEMBL5532716 | 0.67 | BACE1 (0.35) | BACE1CYP2D6BACE2 | |
| SCHEMBL8272039 | 0.67 | HDAC1 (0.48) | PDE4APDE4BPDE4CPDE4DBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232630-A1 | MACROCYCLE DERIVATIVES USEFUL AS INHIBITORS OF beta-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232630-A1 | MACROCYCLE DERIVATIVES USEFUL AS INHIBITORS OF beta-SECRETASE (BACE) | BACE2, BACE1, PSEN2 | PDE4A 2365/4885PDE4B 1501/4885PDE4C 1971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.